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The cellular mechanisms behind prion biosynthesis and metabolism remain unclear. Here we show
that secretin signaling via the secretin receptor regulates abnormal prion protein formation in
prion-infected cells. Animal studies demonstrate that secretin receptor deﬁciency slightly, but
signiﬁcantly, prolongs incubation time in female but not male mice. This gender-speciﬁcity is
consistent with our ﬁnding that prion-infected cells are derived from females. Therefore, our results
provide initial insights into the reasons why age of disease onset in certain prion diseases is reported
to occur slightly earlier in females than males.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Transmissible spongiform encephalopathies or prion diseases
are fatal neurodegenerative disorders that include Creuzfeldt–
Jakob disease in humans, and bovine spongiform encephalopathy
and scrapie in animals. These diseases are characterized by deposi-
tion of a partially protease-resistant abnormal prion protein iso-
form (PrPres), which is produced from the normal cellular
isoform (PrPc) in the central nervous system and lymphoreticular
system [1]. Biosynthesis and metabolism of PrPc and PrPres have
been eagerly investigated at the cellular level using persistentprion-infected cells [2,3], but the cellular mechanism of the
PrPc-to-PrPres conversion remains enigmatic [4–6].
In our efforts examining endogenous factors that affect PrPres
formation in prion-infected cells [7], we identiﬁed secretin (Sct)
signaling as one such factor. Sct is a 27-amino acid peptide
released by endocrine S cells in the duodenum. Subsequently, it
acts on the pancreas to stimulate bicarbonate and water secretion
[8]. Sct is not only capable of crossing the blood–brain barrier but
is also synthesized within the brain [9,10]. Moreover, Sct function
in the central nervous system is a focus of constant attention in
psychiatric disease and autistic spectrum disorder research
[11–13]. The Sct receptor (SctR) is a G-protein coupled receptor
expressed in the brain [10,14] and pancreas [15]. SctR is involved
in neural plasticity and neural networks. Indeed, SctR knockout
mice exhibit impaired synaptic plasticity and social behavior
[16], indicating that SctR-mediated signaling is important for
maintaining brain function.
Here, we report on SctR and Sct gene silencing effects, and also
Sct gene overexpression or exogenous Sct peptide supplementation
on PrPres formation in prion-infected cells. In addition, we
examined disease progression in prion-infected mice deﬁcient in
either SctR or Sct. Finally, we discuss the signiﬁcance of
gender-dependent involvement of SctR-mediated signaling in
prion disease.
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2.1. siRNAs and compounds
Double-stranded small interfering RNAs (siRNAs) for SctR
(Sctr-MSS282665) and Sct (Sct-MSS276963) were purchased from
Invitrogen Corp. (Carlsbad, CA, USA). Mouse or rat Sct peptides
were purchased from Phoenix Pharmaceuticals (Burlingame, CA,
USA) and Tocris Bioscience (Ellisville, MO, USA), respectively.2.2. Expression vectors
Mouse SctR and Sct were cloned by PCR with KOD-plus DNA
polymerase (Toyobo Co. Ltd., Osaka, Japan) from oligo(dT)
primed-cDNA synthesized from mouse neuroblastoma N2a cell
total RNA and ready mouse brain cDNA library (Marathon;
Takara Bio Inc.), respectively. PCR products were inserted into
the pcDNA3.1 Myc/His expression vector (Invitrogen Corp.).
Ligated vectors were introduced into Escherichia coli, and plasmids
of interest were obtained and sequenced. Mutated SctR for rescue
experiments was obtained from cloned SctR by site-directed muta-
genesis using PCR, as described previously [7].2.3. Gene silencing and overexpression
Gene silencing experiments were performed in N2a cells
infected persistently with 22L (N167 cells) or RML prion strain
(ScN2a cells), as described previously [7,17]. These two
scrapie-derived prion strains have distinct differences in both
the phenotype of diseased animals and the responsiveness to
anti-prion compounds [18–20]. In brief, the cells were seeded
onto 6-well plates at a 10% conﬂuence density in 2.4 ml.
Transfections were performed the day after seeding. For gene
silencing, siLentFect (3.0 ll/well, Bio-Rad Laboratories, Inc.) was
used to transfect double-stranded siRNAs. SctR and Sct siRNAs
were used at 10 and 20 nM, respectively. Transfection reagent
without siRNA was used as the negative control for gene silenc-
ing, because in our experience even commercially available, uni-
versal, non-targeting siRNAs produce off-target phenomena [17].
For gene overexpression, TransFectin (3.0 l/well; Bio-Rad
Laboratories, Inc.) was used to transfect expression vectors
(0.4 lg per well). Three days after transfection, cells were har-
vested after washing in PBS.2.4. PrPres and PrPc assay
After rinsing in PBS, cells were lysed in lysis buffer (0.5% sodium
deoxycholate and 0.5% Nonidet P-40 in PBS), and debris eliminated
by brief centrifugation. The protein content of each sample was
measured using the DC protein assay reagent (Bio-Rad
Laboratories, Inc.), with bovine serum albumin as the standard.
PrPres and PrPc levels in cells were assayed by immunoblotting,
as described previously [17,19,21]. In brief, for PrPres, cell lysates
containing equivalent amounts of protein were treated with
10 lg/ml proteinase K for 30 min at 37 C, and PrPres pelleted by
centrifugation. For PrPc, an aliquot of cell lysate containing an
equivalent amount of protein was used without proteinase K treat-
ment. After denaturation in sample buffer with heating, PrP was
separated by SDS–PAGE, and then electrotransfered onto
polyvinylidene diﬂuoride membrane. PrP was detected using
SAF83 antibody, which recognizes residues 126–164 of mouse
PrP (1:5000; SPI-Bio, Massy, France). Immunoreactive signals were
densitometrically analyzed using ImageJ (National Institutes of
Health, Bethesda, MD, USA).2.5. Flotation assay
The ﬂotation assay for detergent-insoluble membrane com-
plexes was performed as described previously [17,22]. In brief,
cells were washed with ice-cold PBS and then lysed on ice in
550 ll TNET solution (25 mM Tris–HCl (pH 7.5), 150 mM NaCl,
5 mM EDTA, and 1% Triton X-100). Lysates were added to an equal
volume of ice-cold 70% Nycodenz™ solution (Cosmo Bio Inc., USA).
Using 800 ll of this mixed solution, 200 ll each of 25%, 22.5%, 20%,
18%, 15%, 12%, and 8% Nycodenz™ solution in TNET was overlaid
sequentially in TLS-55 ultracentrifuge tubes (Hitachi Ltd., Japan).
Ultracentrifugation was performed at 200000g, 4 C for 4 h.
Fractions (200 ll) were collected from top to bottom and analyzed
for PrPc by immunoblotting with SAF83 antibody.
2.6. mRNA quantiﬁcation
Cells were lysed using RNAiso-plus reagent (Takara Bio Inc.).
Total RNA was extracted with FastPure RNA (Takara Bio Inc.), and
cDNA synthesized using a ﬁrst strand cDNA synthesis kit with ran-
dom 6-mer primers (Takara Bio Inc.). mRNA levels were measured
by real-time PCR using SYBR Premix Ex Taq II (Takara Bio Inc.).
Gene expression fold changes were calculated using the 2DDCt
method, with GAPDH as an internal control.
2.7. Animal experiments
SctR, Sct deﬁcient mice, and their wild-type littermates were
generated by mating heterozygous mutant parents [16,23]. Eight-
to twelve-week-old mice were used for intracerebral or intraperi-
toneal prion infection, as described previously [18,19,24]. In brief,
prion inoculation for intracerebral or intraperitoneal infection
was performed using 20 ll or 100 ll, respectively, of 1% (wt/vol)
brain homogenate from a RML prion-infected terminally ill mouse.
Animals were monitored daily until the disease was terminal.
Animal experiments were performed with the approval of the
Animal Experiment Ethical Committee of Tohoku University
(Permit Number: 2011idou-347), and all efforts were made to min-
imize animal suffering.
2.8. Immunoblotting and PET-blot analysis of brain tissue
Disease was conﬁrmed by immunoblotting or
parafﬁn-embedded tissue (PET)-blot analysis for PrPres in the
brain, as described previously [19,25]. In brief, for immunoblotting,
brains were homogenized in 9 volumes of lysis buffer. After
low-speed centrifugation, supernatants were treated with
50 lg/ml proteinase K for 1 h at 37 C. Aliquots were elec-
trophoresed and analyzed by immunoblotting, as described above.
For PET-blot analysis, 5 lm parafﬁn sections were cut and col-
lected onto nitrocellulose membranes, and then dried for overnight
at 60 C. Membranes were dewaxed in xylene, followed by step-
wise rehydration. After wetting with TBST (10 mM Tris HCl (pH
7.8), 100 mM NaCl, and 0.05% Tween 20), sections were digested
with 250 lg/ml proteinase K (in a buffer: 10 mM Tris HCl (pH
7.8), 100 mM NaCl, and 0.1% Brij 35) for overnight at 55 C. After
washing with TBST, sections were treated for 30 min with 3 M
guanidine isothiocyanate. After washing out guanidine using
TBST, immunodetection was performed with anti-PrP-C antibody,
which recognizes residues 214–228 of mouse PrP (1:1500;
Immuno-Biological Laboratories Co. Ltd., Gunma, Japan).
2.9. Gender determination
To determine the gender of mouse neuroblastoma cells, the
sex-determining region Y gene (Sry) on the Y-chromosome was
T. Kimura et al. / FEBS Letters 589 (2015) 2011–2018 2013analyzed by PCR using the primers, TGCATTTATGGTGTGGTCCC and
GCTGCAGGTGCCCAGTG. As a control, the Sox17 gene on chromo-
some 1 was also analyzed by PCR using the primers, GCCGCGTG
GCCATGGATGGC and GCCGTAGTACAGGTGCAGAGC. Sox17 encodes
a member of the Sry-related high-mobility-group box family of
transcription factors, which are involved in the regulation of
embryonic development.
2.10. Statistical analysis
The results of triplicate analyses were examined using one-way
analysis of variance followed by Tukey–Kramer tests for multiple
sample comparisons, or t-tests for two sample comparisons. The
survival rates were calculated using the Kaplan–Meier method,
with signiﬁcance determined by the log-rank method.(A)
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Fig. 1. Effect of SctR gene silencing on PrPres formation in prion-infected cells. (A) Immu
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from top to bottom.3. Results
3.1. SctR gene silencing
SctR gene silencing was examined in two distinct prion
strain-infected cells (N167 and ScN2a) by transfecting a
double-stranded siRNA that targets nucleotides 195–219 of the
SctR coding sequence. siRNA transfection did not affect cell viabil-
ity in either cell type, as shown by cell counting and protein con-
tent assays (data not shown). However, we found an obvious
decrease in PrPres levels in both cell types (Fig. 1A), suggesting that
the mechanism is prion-strain independent. SctR and PrP mRNA
levels were reduced and unchanged, respectively (Fig. 1B). In unin-
fected N2a cells, PrPc protein levels were not altered by siRNA
transfection (Fig. 1C). Rescue experiments performed by(C)
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Fig. 2. Effect of Sct modiﬁcations on PrPres formation in prion-infected cells. (A) Immunoblot of PrPres in N167 and ScN2a cells treated with Sct siRNA (siSct). Graphed data
represent averages and standard deviations from triplicate analyses (⁄, P < 0.01). (B) Graphed data of Sct and PrP mRNA levels in N167 cells treated with siSct. Data represent
triplicate analyses (⁄, P < 0.01). (C) Immunoblot of PrPc in uninfected N2a cells treated with siSct. Graphed data represent triplicate analyses (⁄, P < 0.01). (D) Immunoblot of
PrPres in N167 and ScN2a cells treated with Sct expression vector. Graphed data represent triplicate analyses (⁄, P < 0.01). (E) Immunoblot of PrPc in uninfected N2a cells
treated with Sct expression vector. Graphed data represent triplicate analyses (ns, not signiﬁcant). (F) Immunoblot data of PrPres in N167 cells treated with mouse or rat Sct
peptide. Graphed data represent triplicate analyses (ns, not signiﬁcant; ⁄, P < 0.01 versus 0 nM group, mouse Sct; or 0 to 1 nM groups, rat Sct).
2014 T. Kimura et al. / FEBS Letters 589 (2015) 2011–2018co-transfection of an expression vector containing mutated SctR
gene with silent mutations at the siRNA targeting region showed
recovery from reduced PrPres levels induced by siRNA transfection
(Fig. 1D). Next, we determined if siRNA treatment affected lipid raft
microdomains of the cell membrane, a possible site of
PrPc-to-PrPres conversion or PrPc–PrPres interaction [26–28].Flotation assays for detergent-insoluble lipid raft membrane com-
plexes showed that in N2a cells, SctR siRNA transfection did not
modify PrPc localization in the fractions examined (Fig. 1E).
These results suggest that SctR is involved in PrPres formation
without altering either PrPc levels or lipid raft microdomains of
the cell membrane.
Table 1
Incubation times of SctR- or Sct-deﬁcient mice inoculated with prion.
1) ns, not signiﬁcant; ⁄, P < 0.01; ⁄⁄, P < 0.05.
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To further investigate Sct signaling involvement in PrPres for-
mation, we examined Sct gene silencing in prion-infected cells by
transfection of a double-stranded siRNA targeting nucleotides
305–329 of the Sct coding sequence. Sct siRNA transfection did
not affect cell viability in either cell type (data not shown).
However, we found an obvious decrease in PrPres levels in both
cell types (Fig. 2A). Sct mRNA levels were strikingly reduced
(Fig. 2B). However, PrP mRNA levels were slightly but signiﬁcantly
reduced (Fig. 2B). Consistently, PrPc protein levels in uninfected
N2a cells were signiﬁcantly reduced by Sct siRNA transfection
(Fig. 2C). Therefore, reduced PrPres levels induced by Sct siRNA
transfection are attributable to reduced PrPc levels concomitantly
caused by siRNA transfection.
Next, we tested Sct signaling involvement using another
approach to augment this signaling pathway. Sct gene overexpres-
sion by expression vector transfection showed slight but signiﬁ-
cant increases in PrPres levels in both N167 and ScN2a cells
(Fig. 2D) but contrarily, a slight tendency toward decreased PrPc
levels in uninfected N2a cells (Fig. 2E). Similarly, exogenous sup-
plementation with mouse or rat Sct peptide increased PrPres levels
slightly but signiﬁcantly (Fig. 2F). These results are consistent with
our SctR gene silencing results.3.3. Animal experiments and gender-dependency
We determined if SctR deﬁciency inﬂuences disease progression
in prion-infected animals. We examined SctR-deﬁcient mice
(SctR/), heterozygous mutant mice (SctR+/), and wild-type lit-
termates (SctR+/+) after intracerebral or intraperitoneal inocula-
tion of RML prion to the disease terminal stage (Table 1). Mice
showed disease signs (e.g., motionlessness, irritation, and stagger-
ing), before wasting into the terminal stage of the disease. No obvi-
ous differences were noted in the disease signs and course between
the three genotypes. However, comparing incubation times
between females and males revealed that SctR+/ and SctR+/+
females showed slightly shorter incubation times than males after
either intracerebral or intraperitoneal infection. SctR/ females
had slightly longer incubation times than the other two genotypes
with both intracerebral and intraperitoneal infection.
Similarly, we determined if Sct deﬁciency inﬂuences disease
progression in prion-infected animals. We examined Sct-deﬁcient
mice (Sct/), heterozygous mutant mice (Sct+/), and wild-type
littermates (Sct+/+) after intracerebral or intraperitoneal inocula-
tion of RML prion to the disease terminal stage (Table 1). Mice
showed similar disease signs as described already, before wasting
into the terminal stage of the disease. No obvious differences were
noted in the disease signs and course between the three genotypes.
Fig. 3. PrPres in the brain of prion-infected SctR/mice and SctR+/+ littermates. (A) PET-blot data of PrPres in terminally ill SctR/mice and SctR+/+ littermates. Samples
are from mice representative of each group. Brains sections from uninfected SctR/ and PrP-deﬁcient mice were used as negative controls. (B) Immunoblot of PrPres in
terminally ill SctR/mice and SctR+/+ littermates. Samples are from mice representative of each group. The PrPres glycoform patterns indicated with stars appeared slightly
different and were inconsistent in two independent experiments, although respective samples were identical in both experiments. (C) Immunoblot of PrPc in uninfected
SctR/ mice and SctR+/+ littermates. Brain PrPc levels of mice representative of each group are shown in two independent experiments. (D) PCR data of gender
determination. Sry gene located on chromosome Y was analyzed in conjunction with Sox17 gene on chromosome 1 as a control.
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revealed that all female genotypes had slightly shorter incubation
times than males after either intracerebral or intraperitoneal infec-
tion. In addition, there were no differences in the incubation time
between the genotypes.
PET-blot analysis found no obvious difference in PrPres distri-
bution pattern between the two genotypes (SctR+/+ and
SctR/), which exhibited signiﬁcant incubation time differences
in females (Fig. 3A). Similarly, immunoblotting revealed no consis-
tent difference in either PrPres molecular size or glycoform pattern
between these two genotypes (Fig. 3B). Neither did immunoblot-
ting reveal any signiﬁcant difference in PrPc expression levels
between these two genotypes (Fig. 3C).
Our results show that SctR deﬁciency, and not Sct, enables incu-
bation times in prion-infected female mice to return to similar
levels as those in male mice. Because the effects of SctR deﬁciency
were observed in a female-speciﬁc manner, we examined the gen-
der origin of the cells used (N2a, ScN2a, and N167) for our in vitro
analysis. PCR revealed no sex-determining region Y (Sry) geneproducts from these cells, indicating they are all female-derived
(Fig. 3D; data not shown for ScN2a). Consequently, this result is
consistent with our animal experiment ﬁndings.
4. Discussion
We showed that SctR gene silencing notably reduced PrPres
levels in prion-infected cells without any inﬂuence on PrPc levels
and membrane lipid raft microdomains. In contrast, both Sct gene
overexpression in cells and exogenous Sct peptide supplementa-
tion to cells increased PrPres levels slightly, but signiﬁcantly.
These effects were observed similarly using different scrapie prion
strains. Our ﬁndings suggest that Sct signaling via SctR regulates
PrPres formation in scrapie prion-infected cells.
SctR knockout mice exhibited impaired social behavior, similar
to the clinical features of autism [16], while Sct knockout mice
caused impaired neural progenitor cell survival and affected neu-
robehavioral function in the adult mouse [23]. This indicates that
Sct signaling via SctR is an important signaling pathway for
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prion disease is potentially interesting. In the present study,
Sct/ mice showed no difference in incubation times compared
with Sct+/ or Sct+/+ littermates. In contrast, SctR/ mice had
slightly, but signiﬁcantly, longer incubation times than either
SctR+/ or SctR+/+ littermates. This increase was observed in
females only, suggesting that SctR is related to disease progression
of prion disease in a female-speciﬁc manner.
Gender has been suggested to inﬂuence disease progression in
certain prion diseases [29–33]. Female mice or hamsters have
shorter incubation times in some scrapie prion-infected animal
models [29–31,33]. However, an inverse effect on incubation time
was reported in another scrapie-infected mouse model, and Akhtar
et al. recently suggested that gender effects are not observed in all
mouse strains, and are dependent on a combination of mouse and
prion strains [32]. In the present study, all RML prion-infected
mice, except SctR/ mice, exhibited shorter incubation times in
females than males irrespective of the inoculation route, indicating
that females are more vulnerable to disease progression than
males. In contrast, SctR/ mice showed no signiﬁcant differences
in the incubation time between males and females. These results
suggest that the gender effect in RML-prion-infected animals is
abolished by the absence of SctR expression.
The mouse SctR gene is located on chromosome 1. There is no
literature implicating SctR to female-limited gene products.
However, our animal study suggests that SctR is involved in the
regulation of female-limited gene products that cause shorter incu-
bation times in females in the present animal models. This
female-speciﬁc effect observed in SctR/ mice is consistent with
our observation in prion-infected cells. The SctR gene silencing
effect on PrPres levels was observed in cells derived from females.
Moreover, this observation in prion-infected N2a cells was con-
ﬁrmed in other prion-infected cell types from ﬁbroblast or bone
marrow stromal cell-derived cells (data not shown).
Gender effects were only observed in homozygous
SctR-deﬁcient mice and not in heterozygous SctR- or Sct-deﬁcient
mice. Presumably these restricted effects may be attributed to
SctR and Sct redundancy. SctR belongs to the type II
G-protein-coupled receptor family that also includes VIP, PACAP,
glucagon, and glucagon-like peptide receptors [34]. Sct is able to
bind to these related receptors, which have similar signaling effects
in cells [35–39], and conversely the corresponding peptide hor-
mones in this family can bind SctR [40–42].
Finally, regarding possible mechanistic links between SctR and
PrP, it is unlikely that Sct signaling is linked to the regulation of
PrPc turnover or metabolism, because neither SctR silencing in
the cells nor SctR knockout in the mice modiﬁed PrPc expression
levels. It is also unlikely that SctR directly interacts with PrPc or
PrPres, because such interactions have never been successfully
demonstrated in our study (data not shown). Instead, it might be
presumed that Sct signaling affects PrPc-to-PrPres conversion or
PrPres turnover. However, these presumptions need to be veriﬁed
in future studies.
In conclusion, PrPc-to-PrPres conversion is a key event in prion
formation but remains enigmatic. We show that SctR-mediated
signaling is involved in PrPres formation in prion-infected cells
and disease progression in prion-infected animals, with both ﬁnd-
ings related to gender. Our ﬁndings may provide a clue to resolving
the question of why the age of onset is reportedly earlier in females
than males in certain prion diseases.Acknowledgements
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